Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study
Hajime Takikawa(Teikyo University), Hitoshi Yoshiji(Nara Medical University), Masanori Abe(Nihon University), Hiromasa Ohira(Fukushima Medical University), Tadashi Namisaki(Nara Medical University), Atsushi Takahashi(Fukushima Medical University), Atsushi Tanaka(Medizinische Hochschule Hannover), Minami Yagi(Teikyo University), Yasushi Matsuzaki(Hirosaki University), Akira Honda(Rutgers, The State University of New Jersey)
Cited by 34
Related Papers
Definitions, pathophysiology, and epidemiology of acute cholangitis and cholecystitis: Tokyo Guidelines
|Journal of Hepato-Biliary-Pancreatic Surgery|2007|489
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020
|Journal of Gastroenterology|2021|424
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272
A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update
|Journal of Gastroenterology|2018|242
Evidence‐based clinical practice guidelines for liver cirrhosis 2020
|Hepatology Research|2021|202